A common immune gene variant appears to lower long COVID risk — here's what that means
Long COVID still affects an estimated 400 million people worldwide, and the science of why some people escape it while others don't just got a concrete new lead.
This week's research adds a genetic clue, a viral hiding spot, and a few treatment signals worth watching.
🧬 Your immune genes might influence your long COVID odds
- A Spanish case-control study of 453 hospitalized COVID-19 survivors found that people carrying the HLA-B*15 immune gene variant were significantly less likely to develop long COVID — and that association held up even after adjusting for age, sex, and ICU admission.
- HLA genes help the immune system recognize and flag infected cells. The finding suggests that how well your immune system "sees" the virus during acute infection may shape whether symptoms persist for months afterward.
- A related extended gene haplotype (a cluster of inherited variants) also appeared less often in long COVID patients, though that signal didn't survive full statistical adjustment.
Why it matters: This is one of the cleaner genetic signals to emerge from long COVID research — a specific, named variant with a plausible immune mechanism, not just a statistical blip. The catch: the study is a single Spanish cohort of 453 patients, so replication in larger, more diverse populations is the obvious next step.
Key Findings
🦠 SARS-CoV-2 found in semen months after infection
- An observational study detected SARS-CoV-2 in semen well after acute COVID-19 resolved, raising the possibility that the male genital tract — an immune-privileged site — may act as a long-term viral reservoir.
- Viral persistence is considered one of the leading candidate mechanisms behind long COVID symptoms, and this finding adds a specific anatomical location to that hypothesis. Whether the virus remains replication-competent long-term is still unclear.
🧠 Immune coordination — not just immune strength — may predict neuropsychiatric long COVID
- In a matched study of 27 neuropsychiatric long COVID patients and 27 recovered controls, the long COVID group showed no deficit in raw T-cell or antibody responses to SARS-CoV-2 — but the two arms of the immune response failed to coordinate the way they did in recovered individuals.
- Separately, lower Epstein-Barr virus antibody levels at 3-6 months post-infection were associated with fatigue still reported at 12 months, suggesting EBV-related immune changes may be a useful early marker.
💨 Diaphragm weakness may explain breathlessness that routine tests miss
- Among non-hospitalized long COVID patients with persistent exertional breathlessness, standard cardiopulmonary tests often came back normal — but detailed respiratory muscle assessment pointed to diaphragm impairment as a potential culprit.
- The finding matters because it suggests a treatable, specific mechanism may be hiding behind a frustratingly normal-looking workup, at least in some patients.
🏥 Multidisciplinary rehab produces real-world gains — but timing matters
- A retrospective cohort study tracking adults through a structured long COVID rehabilitation program found meaningful improvements in clinical and patient-reported outcomes, and also found that longer waits from referral to assessment were associated with worse results.
- The practical implication: the program works well enough to document, but delays in getting patients in the door appear to erode some of that benefit.
📋 Canada just published 100+ long COVID recommendations — here's the short version
- McMaster University's Cochrane Canada and GRADE Centres, with support from the Public Health Agency of Canada, synthesized over 100 recommendations covering prevention, diagnosis, treatment, neurological care, pediatric considerations, and health system supports into a single guideline document.
- A summary version was published specifically for general practitioners, who are often the first and only point of contact for long COVID patients.
📊 Long COVID is likely underdiagnosed — and not equally across groups
- A study of care-seeking patients in the Midwestern US found that even among people presenting with long COVID symptoms, diagnosis rates varied in ways that suggest systematic underdiagnosis and disparities tied to patient characteristics.
- The study was designed specifically to surface gaps between who has symptoms and who gets a formal diagnosis — a distinction that matters for both treatment access and prevalence estimates.
Implications
The week's research keeps circling the same unresolved problem: long COVID is heterogeneous enough that no single mechanism, marker, or treatment fits everyone. A protective immune gene variant, a viral reservoir in semen, and miscoordinated immune responses all point in different directions — which raises the uncomfortable question of whether "long COVID" is one condition or several traveling under the same name.
Studies in this issue
Primary sources used for this newsletter.
- Detailed Immune Gene Study of Long COVID Shows HLA-B*15 May Offer Protectionmain storyHLA2026-11-13PMID 43023789
- Long COVID with brain-related symptoms is linked to changes in coordinated immune responses to COVID-19 and lower immune response to Epstein-Barr virus up to 12 months after infectionkey findingJournal of virology2026-11-13PMID 43023729
- Ongoing breathlessness after mild COVID-19 may be linked to weakened breathing musclekey findingFrontiers in physiology2026-11-11PMID 43010943
- Differences in Long COVID Diagnosis in Midwestern Patients and How to Find Undiagnosed Caseskey findingPreventive medicine2026-11-10PMID 43009070
- Finding SARS-CoV-2 in semen months after COVID-19 suggests possible low-level ongoing virus presencekey findingAndrology2026-11-10PMID 43004827
- Canadian guidelines summary for doctors on caring for long COVID patientskey findingThe European journal of general practice2026-11-12PMID 43016329
- Results of a team-based rehabilitation program for adults with long COVIDkey findingBMC public health2026-11-10PMID 43009877
Continue reading
All Long Covid issuesGet the next Long Covid issue
Seven papers, once a week. Free.